Timur Dogan
Technik-/Wissenschafts-/F&E-Leiter bei CARDIO DIAGNOSTICS HOLDINGS, INC.
Vermögen: 92 665 $ am 30.04.2024
Profil
Timur Dogan is currently the Chief Technology Officer at Cardio Diagnostics Holdings, Inc. He previously held the same position at Cardio Diagnostics, Inc. Dr. Dogan obtained his undergraduate, graduate, and doctorate degrees from the University of Iowa.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.04.2024 | 128 345 ( 0,59% ) | 92 665 $ | 30.04.2024 |
Aktive Positionen von Timur Dogan
| Unternehmen | Position | Beginn |
|---|---|---|
| CARDIO DIAGNOSTICS HOLDINGS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 25.10.2022 |
Ehemalige bekannte Positionen von Timur Dogan
| Unternehmen | Position | Ende |
|---|---|---|
Cardio Diagnostics, Inc.
 Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Timur Dogan
| University of Iowa | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CARDIO DIAGNOSTICS HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Cardio Diagnostics, Inc.
Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Health Services |
